HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Phase 2 randomized, double-blind study of IL-17 targeting with secukinumab in atopic dermatitis.

AuthorsBenjamin Ungar, Ana B Pavel, Randall Li, Grace Kimmel, John Nia, Peter Hashim, Hee Jin Kim, Margot Chima, Anjali S Vekaria, Yeriel Estrada, Hui Xu, Xiangyu Peng, Giselle K Singer, Danielle Baum, Yasaman Mansouri, Mark Taliercio, Emma Guttman-Yassky
JournalThe Journal of allergy and clinical immunology (J Allergy Clin Immunol) Vol. 147 Issue 1 Pg. 394-397 (01 2021) ISSN: 1097-6825 [Electronic] United States
PMID32428528 (Publication Type: Clinical Trial, Phase II, Letter, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
Chemical References
  • Antibodies, Monoclonal, Humanized
  • IL17A protein, human
  • Interleukin-17
  • secukinumab
Topics
  • Adult
  • Antibodies, Monoclonal, Humanized (administration & dosage)
  • Dermatitis, Atopic (drug therapy, immunology, pathology)
  • Double-Blind Method
  • Drug Delivery Systems
  • Female
  • Humans
  • Interleukin-17 (antagonists & inhibitors, immunology)
  • Th17 Cells (immunology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: